Psychotropic drugs in acute intermittent porphyria

Clinical Pharmacology and Therapeutics

Volumn 66, Issue 3, 1999, Pages 323-325

  Holroyd, Suzanne ^a   Seward, Robert L ^b  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BUTALBITAL; CHLORDIAZEPOXIDE; CLONAZEPAM; CLOZAPINE; LORAZEPAM; NORTRIPTYLINE; OLANZAPINE; PHENOBARBITAL; PSYCHOTROPIC AGENT; RISPERIDONE; SECOBARBITAL; SERTRALINE; TRAZODONE; TRIFLUOPERAZINE; VENLAFAXINE;

ACUTE INTERMITTENT PORPHYRIA; ADULT; ARTICLE; CASE REPORT; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPOTENSION; PARKINSONISM; PRIORITY JOURNAL; RELAPSE; SUICIDE ATTEMPT;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DRUG INTERACTIONS; FEMALE; HUMANS; MIDDLE AGED; PORPHYRIA, ACUTE INTERMITTENT; PSYCHOTROPIC DRUGS; RECURRENCE;

EID: 0032823171     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(99)70041-X     Document Type: Article

References (15)

1. 1. Kappas A, Sassa S, Galbraith RA. The porphyrins. In: Scriver CR, Beaudet AL, Sly WS, et al, editors. The metabolic basis of inherited disease. 65th ed. New York: McGraw-Hill; 1989.
2. 2. De Matteis F. Drugs and porphyria. S Afr Med J 1971: 126-33.
3. 3. Cowger ML, Labbe RF. Contraindications of biological oxidation inhibitors in the treatment of porphyria. Lancet 1965;1:88-9.
4. 4. Wassif WS, Deacon AC, Floderus Y, Thunell S, Peters TJ. Acute intermittent porphyria: diagnostic conundrums. Eur J Clin Chem Clin Biochem 1994;32:915-21.
5. 5. Patience DA, Blackwood DH, McColl KE, Moore MR. Acute intermittent porphyria and mental illness: a family study. Acta Psychiatr Scand 1991;89:262-7.
6. 6. Berg M. Acute porphyria: clinical and pathological observations. Arch Intern Med 1945;76:335-40.
7. 7. Lai CW, Hung TP, Lin WSJ. Blindness of cerebral origin in acute intermittent porphyria: report of a case and postmortem examination. Arch Neurol 1977;34:310-2.
8. 8. Hierons R. Changes in the nervous system in acute porphyria. Brain 1957;80:176-92.
9. 9. King PH, Bragdon AC. MRI reveals multiple reversible cerebral lesions in an attack of acute intermittent porphyria. Neurology 1991;41:1300-2.
10. 10. Verma A, Nye JS, Snyder SH. Porphyrins are endogenous ligands for the mitochondrial (peripheral-type) benzodiazepine receptor. Proc Natl Acad Sci USA 1987;84:2256-60.
11. 11. Moore MR. International review of drugs in acute porphyria. Int J Biochem 1980;12:1089-97.
12. 12. Drugdex System. Gelman CR, Rumack BH, Hess AJ, editors. vol 93. Englewood (CO): Micromedex; 1997.
13. 13. Krummel SJ, Wesner RB. Exacerbation of acute intermittent porphyria by nortriptyline. Drug Intell Clin Pharm 1986;20:487-8.
14. 14. Vas FJ, Salcedo MS. Fluoxetine treatment of depressive symptoms in acute intermittent porphyria [letter]. J Clin Psychiatry 1991;52:138.
15. 15. Talmud J. Antidepressants in patients with porphyria [letter]. S Afr Med J 1995;85:182-3.